Axa
NTLA icon

Axa’s Intellia Therapeutics NTLA Stock Holding History

Axa’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8,223
Closed -$226K – 1107
2024
Q1 		$226K Buy
+8,223
New +$228K ﹤0.01% 1014
2022
Q4 		– Sell
-38,287
Closed -$2.14M – 1197
2022
Q3 		$2.14M Buy
38,287
+164
+0.4% +$10.2K 0.01% 749
2022
Q2 		$1.97M Sell
38,123
-741
-2% -$37.6K 0.01% 778
2022
Q1 		$2.82M Hold
38,864
– – 0.01% 772
2021
Q4 		$4.59M Buy
38,864
+463
+1% +$58K 0.01% 683
2021
Q3 		$5.15M Buy
38,401
+1,415
+4% +$214K 0.01% 671
2021
Q2 		$5.99M Buy
+36,986
New +$2.88M 0.02% 658

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Axa's NTLA Position: Q2 2024 in Review

Axa sold out of Intellia Therapeutics (NTLA) in Q2 2024, closing a stake of 8,223 shares — an estimated $226K sold.

Axa first reported a position in NTLA in Q2 2021 and held it in 7 quarters. The position peaked at $5.99M in Q2 2021. 290 funds tracked by Wall St. Rank hold NTLA as of Q2 2024.

  • Axa reported no remaining Intellia Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Axa sold 8,223 Intellia Therapeutics shares in Q2 2024, an estimated $226K.
  • Axa first reported a position in Intellia Therapeutics in Q2 2021 and held it in 7 quarters.
  • Axa's Intellia Therapeutics position peaked at $5.99M in Q2 2021.
  • 290 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2024.

Based on Axa's 13F filing for Q2 2024, filed 14 Aug 2024.